EQUITY RESEARCH MEMO

Horus Pharma

Generated 5/11/2026

Executive Summary

Conviction (model self-assessment)65/100

Horus Pharma is an independent French pharmaceutical company founded in 2003, specializing in ophthalmology and dermatology. It is a pioneer in preservative-free ophthalmic products, with a portfolio spanning medicinal products, medical devices, food supplements, and a surgical division. The company operates internationally through subsidiaries across Europe and distribution agreements in numerous other countries, leveraging its expertise in niche therapeutic areas. Its focus on preservative-free solutions addresses growing demand for safer ocular treatments, positioning it as a key player in the European ophthalmology market.

Upcoming Catalysts (preview)

  • Q3 2026Launch of new preservative-free ophthalmic product70% success
  • Q4 2026Expansion of surgical division into new European markets60% success
  • TBDStrategic partnership for dermatology product distribution50% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)